Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses

English version České info

Dengue viruses (DENVs) are emerging, mosquito-borne flaviviruses which cause dengue fever and dengue hemorrhagic fever. The DENV complex consists of 4 serotypes designated DENV1-DENV4. Following natural infection with DENV, individuals develop serotype specific, neutralizing antibody responses. Monoclonal antibodies (MAbs) have been used to map neutralizing epitopes on dengue and other flaviviruses. Most serotype-specific, neutralizing MAbs bind to the lateral ridge of domain III of E protein (EDIII). It has been widely assumed that the EDIII lateral ridge epitope is conserved within each DENV serotype and a good target for vaccines. Using phylogenetic methods, we compared the amino acid sequence of 175 E proteins representing the different genotypes of DENV3 and identified a panel of surface exposed amino acids, including residues in EDIII, that are highly variant across the four DENV3 genotypes. The variable amino acids include six residues at the lateral ridge of EDIII. We used a panel of DENV3 mouse MAbs to assess the functional significance of naturally occurring amino acid variation. From the panel of antibodies, we identified three neutralizing MAbs that bound to EDIII of DENV3. Recombinant proteins and naturally occurring variant viruses were used to map the binding sites of the three MAbs. The three MAbs bound to overlapping but distinct epitopes on EDIII. Our empirical studies clearly demonstrate that the antibody binding and neutralization capacity of two MAbs was strongly influenced by naturally occurring mutations in DENV3. Our data demonstrate that the lateral ridge “type specific” epitope is not conserved between strains of DENV3. This variability should be considered when designing and evaluating DENV vaccines, especially those targeting EDIII.

Vyšlo v časopise: Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses. PLoS Pathog 6(3): e32767. doi:10.1371/journal.ppat.1000821
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1000821

Souhrn

Zdroje

1. HalsteadSB

2007 Dengue. Lancet 370 1644 1652

2. SabinAB

1952 Research on dengue during World War II. Am J Trop Med Hyg 1 30 50

3. ImrieA

MeeksJ

GuraryA

SukhbaatarM

TruongTT

2007 Antibody to Dengue 1 Detected More Than 60 Years after Infection. Viral Immunology 20 672 675

4. Rico-HesseR

2003 Microevolution and virulence of dengue viruses. Adv Virus Res 59 315 341

5. BlaneyJEJr

MatroJM

MurphyBR

WhiteheadSS

2005 Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 79 5516 5528

6. EndyTP

NisalakA

ChunsuttitwatS

VaughnDW

GreenS

2004 Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 189 990 1000

7. ZuluetaA

MartinJ

HermidaL

AlvarezM

ValdesI

2006 Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res 121 65 73

8. LiL

BarrettAD

BeasleyDW

2005 Differential expression of domain III neutralizing epitopes on the envelope proteins of West Nile virus strains. Virology 335 99 105

9. SanchezMD

PiersonTC

McAllisterD

HannaSL

PufferBA

2005 Characterization of neutralizing antibodies to West Nile virus. Virology 336 70 82

10. RoehrigJT

2003 Antigenic structure of flavivirus proteins. Adv Virus Res 59 141 175

11. ModisY

OgataS

ClementsD

HarrisonSC

2003 A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100 6986 6991

12. ModisY

OgataS

ClementsD

HarrisonSC

2005 Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79 1223 1231

13. NybakkenGE

NelsonCA

ChenBR

DiamondMS

FremontDH

2006 Crystal structure of the West Nile virus envelope glycoprotein. J Virol 80 11467 11474

14. ReyFA

HeinzFX

MandlC

KunzC

HarrisonSC

1995 The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375 291 298

15. Sukupolvi-PettyS

AustinSK

PurthaWE

OliphantT

NybakkenGE

2007 Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes. J Virol 81 12816 12826

16. CrillWD

ChangG-JJ

2004 Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes. J Virol 78 13975 13986

17. GromowskiGD

BarrettADT

2007 Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366 349 360

18. PiersonTC

FremontDH

KuhnRJ

DiamondMS

2008 Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4 229 238

19. PiersonTC

DiamondMS

2008 Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 10 e12

20. HermidaL

BernardoL

MartinJ

AlvarezM

PradoI

2006 A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24 3165 3171

21. EtemadB

BatraG

RautR

DahiyaS

KhanamS

2008 An Envelope Domain III-based Chimeric Antigen Produced in Pichia pastoris Elicits Neutralizing Antibodies Against All Four Dengue Virus Serotypes. Am J Trop Med Hyg 79 353 363

22. KrausAA

MesserW

HaymoreLB

de SilvaAM

2007 Comparison of Plaque- and Flow Cytometry- Based Methods for Measuring Dengue Virus Neutralization. J Clin Microbiol 45 3777 3780

23. SerafinIL

AaskovJG

2001 Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies. Archives of Virology 146 2469 2479

24. ChennaR

SugawaraH

KoikeT

LopezR

GibsonTJ

2003 Multiple sequence alignment with the Clustal series of programs. Nucl Acids Res 31 3497 3500

25. HalsteadSB

2003 Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60 421 467

26. LanciottiRS

LewisJG

GublerDJ

TrentDW

1994 Molecular evolution and epidemiology of dengue-3 viruses. J Gen Virol 75 65 75

27. GromowskiGD

BarrettND

BarrettAD

2008 Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82 8828 8837

28. RajamanonmaniR

NkenfouC

ClancyP

YauYH

ShochatSG

2009 On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol 90 799 809

29. NybakkenGE

OliphantT

JohnsonS

BurkeS

DiamondMS

2005 Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437 764 769

30. BeasleyDW

BarrettAD

2002 Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol 76 13097 13100

31. LokSM

KostyuchenkoV

NybakkenGE

HoldawayHA

BattistiAJ

2008 Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15 312 317

32. MukhopadhyayS

KuhnRJ

RossmannMG

2005 A structural perspective of the flavivirus life cycle. 3 13 22

33. VolkDE

BeasleyDW

KallickDA

HolbrookMR

BarrettAD

2004 Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J Biol Chem 279 38755 38761

34. VolkDE

LeeYC

LiX

ThiviyanathanV

GromowskiGD

2007 Solution structure of the envelope protein domain III of dengue-4 virus. Virology 364 147 154

35. YuS

WuuA

BasuR

HolbrookMR

BarrettAD

2004 Solution structure and structural dynamics of envelope protein domain III of mosquito- and tick-borne flaviviruses. Biochemistry 43 9168 9176